Posted by Michael Wonder on 27 Jan 2026
Libevitug approved in China as first in class treatment for hepatitis D
27 January 2026 - Huahui Health announced that China NMPA has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection in adults with or without compensated cirrhosis.
Libevitug is a human monoclonal antibody targeting the PreS1 domain of the large envelope protein of hepatitis B virus and hepatitis D virus, thereby blocking viral entry into hepatocytes.
